|
15 May 2023 |
BiOneCure Therapeutics and Nanjing Leads Biolabs Join Forces to Develop Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment
|
|
15 May 2023 |
AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023
|
|
15 May 2023 |
U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine
|
|
15 May 2023 |
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
|
|
15 May 2023 |
Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis English
|
|
15 May 2023 |
Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
|
|
15 May 2023 |
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
|
|
13 May 2023 |
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
|
|
13 May 2023 |
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
|
|
13 May 2023 |
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
|
|
13 May 2023 |
Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
|
|
12 May 2023 |
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
|
|
11 May 2023 |
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
|
|
11 May 2023 |
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
|
|
11 May 2023 |
Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism
|
|
11 May 2023 |
CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology
|
|
11 May 2023 |
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
|
|
10 May 2023 |
Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV
|
|
10 May 2023 |
Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
|
|
10 May 2023 |
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
|
